These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 15904951)

  • 1. BRAF polymorphisms and the risk of ovarian cancer of low malignant potential.
    Kelemen L; James M; Spurdle A; Campbell I; Chang-Claude J; Peel D; Anton-Culver H; Berchuck A; Schildkraut J; Whittemore A; McGurie V; DiCioccio RA; Duffy D; Chenevix-Trench G
    Gynecol Oncol; 2005 Jun; 97(3):807-12. PubMed ID: 15904951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D; Hirschmann A; Löhrs U; Diebold J
    Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Single nucleotide polymorphisms in cell cycle regulator p21 and p27 genes are associated with susceptibility to epithelial ovarian cancer].
    Jin X; Kang S; Wang N; Xing YP; Li Y
    Zhonghua Fu Chan Ke Za Zhi; 2008 Mar; 43(3):209-12. PubMed ID: 18788572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
    Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
    Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of BRAF V600E mutant protein in epithelial ovarian tumors.
    Preusser M; Capper D; Berghoff AS; Horvat R; Wrba F; Schindl M; Schoppmann SF; von Deimling A; Birner P
    Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):159-64. PubMed ID: 22820660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No Evidence for BRAF as a melanoma/nevus susceptibility gene.
    Jackson S; Harland M; Turner F; Taylor C; Chambers PA; Randerson-Moor J; Swerdlow AJ; dos Santos Silva I; Beswick S; Bishop DT; Newton Bishop JA
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):913-8. PubMed ID: 15824163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphatic vascular invasion in ovarian serous tumors of low malignant potential with stromal microinvasion: a case control study.
    Sangoi AR; McKenney JK; Dadras SS; Longacre TA
    Am J Surg Pathol; 2008 Feb; 32(2):261-8. PubMed ID: 18223329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis.
    Pearce CL; Hirschhorn JN; Wu AH; Burtt NP; Stram DO; Young S; Kolonel LN; Henderson BE; Altshuler D; Pike MC
    J Natl Cancer Inst; 2005 Jan; 97(1):51-9. PubMed ID: 15632380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
    Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. E-cadherin gene polymorphisms and haplotype associated with the occurrence of epithelial ovarian cancer in Chinese.
    Li Y; Liang J; Kang S; Dong Z; Wang N; Xing H; Zhou R; Li X; Zhao X
    Gynecol Oncol; 2008 Feb; 108(2):409-14. PubMed ID: 18035404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort.
    Haiman CA; Stram DO; Pike MC; Kolonel LN; Burtt NP; Altshuler D; Hirschhorn J; Henderson BE
    Hum Mol Genet; 2003 Oct; 12(20):2679-92. PubMed ID: 12944421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
    Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
    Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Association of three single nucleotide polymorphisms of the E-cadherin gene with susceptibility to epithelial ovarian carcinoma].
    Liang J; Li Y; Wang N
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Apr; 25(2):183-6. PubMed ID: 18393242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
    Brustmann H
    Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors.
    Jamieson S; Alexiadis M; Fuller PJ
    Gynecol Oncol; 2004 Dec; 95(3):603-9. PubMed ID: 15581971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS variation and risk of endometriosis.
    Zhao ZZ; Nyholt DR; Le L; Martin NG; James MR; Treloar SA; Montgomery GW
    Mol Hum Reprod; 2006 Nov; 12(11):671-6. PubMed ID: 16973828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea.
    Han W; Kang D; Lee JE; Park IA; Choi JY; Lee KM; Bae JY; Kim S; Shin ES; Lee JE; Shin HJ; Kim SW; Kim SW; Noh DY
    Clin Cancer Res; 2005 Jul; 11(13):4775-8. PubMed ID: 16000574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
    Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
    BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do polymorphisms and haplotypes of mismatch repair genes modulate risk of sporadic colorectal cancer?
    Tulupova E; Kumar R; Hanova M; Slyskova J; Pardini B; Polakova V; Naccarati A; Vodickova L; Novotny J; Halamkova J; Hemminki K; Vodicka P
    Mutat Res; 2008 Dec; 648(1-2):40-5. PubMed ID: 18851982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions.
    Emerson RE; Wang M; Liu F; Lawrence WD; Abdul-Karim FW; Cheng L
    Int J Gynecol Pathol; 2007 Oct; 26(4):387-94. PubMed ID: 17885488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.